MALVERN, Pa.--(BUSINESS WIRE)--Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in 2022), today announced they will be operating under the new name Resolian — fully integrating the companies into one organization. This brings together the companies’ established bioanalytical laboratories and experts in the U.S., U.K., and most recently in Australia, as Resolian continues to expand and support the growing need for small and large molecule bioanalytical and analytical services globally.
Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its new 20,000-square-foot (1,858-square-meter) bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia.
Alliance Pharma Opens State-of-the-Art Bioanalytical Laboratory in Brisbane
Alliance Pharma continued its expansion plans with the opening of a new bio analytical lab in Brisbane, Australia, to support preclinical and clinical testing.
Alliance Pharma, a global provider of bioanalytical, DMPK, and CMC testing services for the pharma and biopharma industry, has opened its new 20,000-sq.-ft. bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia.
Alliance Pharma has expanded its executive team with the addition of four C-suite hires as the bioanalytical services company continues its growth spurt.
Alliance Pharma, a global leader in bioanalytical, DMPK and CMC testing services in the pharmaceutical and biopharmaceutical industry, has grown its leadership team by four, bringing on board a new Chief Operating Officer (COO), Chief Commercial Officer (CCO), Chief Financial Officer (CFO), and Chief People Officer (CPO).
MALVERN, Pa.--(BUSINESS WIRE)--Alliance Pharma (Alliance), a global leader in bioanalytical, DMPK and CMC testing services in the pharmaceutical and biopharmaceutical industry, has grown their leadership team by four, bringing on board a new Chief Operating Officer (COO), Chief Commercial Officer (CCO), Chief Financial Officer (CFO), and Chief People Officer (CPO). These leaders will support continued global expansion, which includes Alliance’s recent acquisition of U.K.-based Drug Development Solutions (DDS) from LGC and new bioanalytical laboratory opening in Australia in November.
British healthcare company Alliance Pharma suffered a major blow today after it announced boss Peter Butterfield could lose his job as company director following an investigation by the UK competition watchdog.
U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into Australia